Correlation Between Cns Pharmaceuticals and Sonnet Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cns Pharmaceuticals and Sonnet Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cns Pharmaceuticals and Sonnet Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cns Pharmaceuticals and Sonnet Biotherapeutics Holdings, you can compare the effects of market volatilities on Cns Pharmaceuticals and Sonnet Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cns Pharmaceuticals with a short position of Sonnet Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cns Pharmaceuticals and Sonnet Biotherapeutics.

Diversification Opportunities for Cns Pharmaceuticals and Sonnet Biotherapeutics

0.51
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Cns and Sonnet is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding Cns Pharmaceuticals and Sonnet Biotherapeutics Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sonnet Biotherapeutics and Cns Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cns Pharmaceuticals are associated (or correlated) with Sonnet Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sonnet Biotherapeutics has no effect on the direction of Cns Pharmaceuticals i.e., Cns Pharmaceuticals and Sonnet Biotherapeutics go up and down completely randomly.

Pair Corralation between Cns Pharmaceuticals and Sonnet Biotherapeutics

Given the investment horizon of 90 days Cns Pharmaceuticals is expected to generate 1.12 times more return on investment than Sonnet Biotherapeutics. However, Cns Pharmaceuticals is 1.12 times more volatile than Sonnet Biotherapeutics Holdings. It trades about 0.22 of its potential returns per unit of risk. Sonnet Biotherapeutics Holdings is currently generating about 0.05 per unit of risk. If you would invest  10.00  in Cns Pharmaceuticals on November 18, 2024 and sell it today you would earn a total of  4.00  from holding Cns Pharmaceuticals or generate 40.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Cns Pharmaceuticals  vs.  Sonnet Biotherapeutics Holding

 Performance 
       Timeline  
Cns Pharmaceuticals 

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Cns Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Cns Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.
Sonnet Biotherapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Cns Pharmaceuticals and Sonnet Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cns Pharmaceuticals and Sonnet Biotherapeutics

The main advantage of trading using opposite Cns Pharmaceuticals and Sonnet Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cns Pharmaceuticals position performs unexpectedly, Sonnet Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will offset losses from the drop in Sonnet Biotherapeutics' long position.
The idea behind Cns Pharmaceuticals and Sonnet Biotherapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Share Portfolio
Track or share privately all of your investments from the convenience of any device